Savara (SVRA) Cash from Investing Activities (2010 - 2026)
Savara (SVRA) posted quarterly Cash from Investing Activities of $38.8 million for Q1 2026, up 32.22% year-over-year from $29.3 million in Q1 2025, and up 141.45% quarter-over-quarter from -$93.6 million in Q4 2025.
Analysis
Savara (SVRA) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Cash from Investing Activities for 17 consecutive years, with $38.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 32.22% year-over-year to $38.8 million; the TTM figure through Mar 2026 stood at -$9.0 million (up 58.0% YoY), while the FY2025 annual figure was -$18.4 million, up 53.83% from the prior year.
- Cash from Investing Activities improved to $38.8 million in Q1 2026 per SVRA's latest filing, from -$93.6 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $53.7 million in Q1 2022 and bottomed at -$98.2 million in Q3 2024.
- Historically, Cash from Investing Activities has averaged -$1.4 million across 5 years, with a median of $17.9 million in 2024.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities tumbled 4569.64% — and 2024, when it surged 3036.18%.
- Savara's Cash from Investing Activities stood at -$59.2 million in 2022, then jumped by 111.1% to $6.6 million in 2023, then jumped by 172.33% to $17.9 million in 2024, then slumped by 622.85% to -$93.6 million in 2025, then jumped by 141.45% to $38.8 million in 2026.
- Business Quant data shows SVRA's Cash from Investing Activities at $38.8 million in Q1 2026, -$93.6 million in Q4 2025, and $21.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | 32.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.60 Mn |
| Mar 31, 2026 | 38.78 Mn |
| Dec 31, 2025 | -93.56 Mn |
| Sep 30, 2025 | 21.47 Mn |
| Jun 30, 2025 | 24.33 Mn |
| Mar 31, 2025 | 29.33 Mn |
| Dec 31, 2024 | 17.90 Mn |
| Sep 30, 2024 | -98.17 Mn |
| Jun 30, 2024 | 29.54 Mn |
| Mar 31, 2024 | 10.79 Mn |
| Dec 31, 2023 | 6.57 Mn |
| Sep 30, 2023 | -56.59 Mn |
| Jun 30, 2023 | -1.01 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | -59.21 Mn |
| Sep 30, 2022 | 33.00 Mn |
| Jun 30, 2022 | 25.20 Mn |
| Mar 31, 2022 | 53.67 Mn |
| Dec 31, 2021 | -1.27 Mn |
| Sep 30, 2021 | 12.98 Mn |